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Shoulder arthroscopyAbstract Background: Postoperative pain is difﬁcult to be managed with the use of opioids anal-
gesia alone, so multimodal pain management is a method to improve postoperative analgesia with
minimal side effects. Pregabalin has an analgesic and opioid sparing effects in postoperative anal-
gesia. The objective of the present study was to evaluate the effect of premedication with pregabalin
on postoperative analgesia in patients undergoing shoulder arthroscopy.
Methods: Eighty patients ASA I-II and aged 18–60 years undergoing elective shoulder arthroscopy
were randomized to receive two doses of either placebo or pregabalin 300 mg 12 h and 1 h before
surgery. Anesthesia was induced with thiopental (3–5 mg/kg) and atracurium (0.5 mg/kg) and main-
tained with isoﬂurane with O2. Patients were studied at 1, 4, 8, 12 and 24 h postoperatively for
Visual Analogue Scale (VAS), nalbuphine consumption (was given when VAS > 4), satisfaction
score and side effects of pregabalin.
Results: The VAS scores of the pregabalin group were signiﬁcantly lower than the control group at
1, 4 and 8 h after surgery. The total nalbuphine consumption at 24 h postoperatively of pregabalin
group (33.8 + 6.89) was highly signiﬁcant lower than the control group (46.4 + 5.72) (p< 0.001).
There were no signiﬁcant differences between groups in somnolence-dizziness and nausea-vomiting.
The satisfaction score was higher in the pregabalin group.
Conclusion: A 300 mg pregabalin administered 12 h and 1 h preoperatively is a safe and effective
method in management of pain after shoulder arthroscopy.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.D license.1. Introduction
Advances in surgical techniques have led to increasingly more
procedures being performed on an outpatient basis [1–4] as
shoulder arthroscopy. Postoperative pain is the most common
reason for delayed discharge, and the main reason for unantic-
ipated hospital admission [5]. Opioid medications have been
still the mainstay of postoperative pain management, but these
medications have serious adverse effects [6].
Table 1 Demographic data and duration of surgery.
Group I Group II
Age 42.15 ± 13.08 41.3 ± 14.7
Sex M/F 16/24 22/18
Weight 79.3 ± 7.88 75.2 ± 7.54
Height 170 ± 7.11 166.15 ± 6.38
Duration of surgery (min) 82.5 ± 15.52 77 ± 19.89
Group I: placebo, Group II: pregabalin, M: male, F: female. Data
were expressed as mean ± standard deviation and number of
patients.
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resection of bursal tissue, insertion of hardware, and soft tissue
distension from irrigation ﬂuid. Many patients are hospitalized
overnight to control pain that results from this intervention.
This may be because the postoperative pain is under-treated
in the outpatient setting [7].
Pregabalin is the active S-enantiomer of racemic 3-isobutyl
GABA [6] and binds to the alpha 2-delta (a2-d) subunit of the
presynaptic, voltage-gated calcium channels that are widely
distributed throughout the peripheral and central nervous sys-
tem [8–10]. The probable mechanism of action of pregabalin
via, potent binding at this site reduces calcium inﬂux at nerve
terminals and therefore reduces the release of several neuro-
transmitters including glutamate, norepinephrine and sub-
stance P [11,12]. Pregabalin was used in the treatment of
chronic pain conditions, but recently it has used in the treat-
ment of acute postoperative pain [13–18], but there was not
any research has been done to study its effect on acute postop-
erative shoulder pain. The aim of the study is to evaluate the
efﬁcacy and safety of preoperative pregabalin on acute postop-
erative pain in patients scheduled for shoulder arthroscopy.
2. Methods
After approval from the local ethical committee of the Faculty
of Medicine, Menouﬁya University, written informed consents
were obtained from the patients who were scheduled to under-
go elective shoulder arthroscopy. Patients with the following
characteristics were excluded from the study: age <18 years;
age >60 years; pregnant; allergic and/or contraindicated to
the study drugs; American Society of Anesthesiologists
(ASA) score III and above; having drug and/or alcohol addic-
tion, renal failure, diabetes mellitus or epilepsy; and currently
using opioids for chronic pain and/or any of the drugs studied.
A total of 80 patients, ASA I-II and aged 18–60 years were in-
cluded in the study. Patients were randomly assigned to one of
two groups using a closed envelope randomization schedule.
The patients in Group I (placebo, n= 40) received ‘placebo’
two doses, 12 h apart prior to the operation (one 12 h and
the other 1 h preoperative). Patients in Group II (pregabalin
n= 40) received pregabalin 300 mg at the same time intervals
as Group I patients. In the operating room, a crystalloid infu-
sion was started through an IV cannula and the mean arterial
blood pressure (MAP), heart rate (HR) and peripheral oxygen
saturation (SpO2) were monitored. General anaesthesia was
induced with thiopental sodium (3–5 mg/kg), fentanil
(1 lg/kg) and atrachurium (0.5 mg/kg) and maintained with
isoﬂurane and O2. Isoﬂurane concentration was adjusted to
maintain adequate depth of anaesthesia. Before onset of sur-
gery, intra-articular injection of 10 ml adrenalized 1:200000
bupivacaine 0.25% was performed to all study patients (adren-
aline was giving due to its vasoconstrictor effect allowing
reduction of bleeding at the operative ﬁeld and better arthro-
scopic view). No other analgesic was administered during the
surgery. After the end of surgery, all patients received intrave-
nous diclofenac 75 mg as a routine analgesic. The patients were
taught how to express the level of pain they experienced using
a 10-point Visual Analogue Scale (VAS), with 0 indicating no
pain and 10 indicating the worst possible pain. Incremental
titrating doses of nalbuphine (4 mg/dose) were given when
indicated (if VASP 4) due to unavailability of PCA modalityin our institute. Anxiety scores, vital signs, pain scores, Nu-
meric Sedation Scores (NSS; 1 = completely awake,
2 = awake but drowsy, 3 = asleep but responsive to verbal
commands, 4 = asleep but responsive to tactile stimulus,
5 = asleep and not responsive to any stimuli), nalbuphine con-
sumption and adverse effects such as nausea, vomiting, pruri-
tus, urinary retention, somnolence, dizziness, vision
abnormalities (double or blurred) and headache were re-
corded. Except for patient satisfaction score which was mea-
sured at 24 h postoperatively on a numerical score of 1–4
(1 = poor, 2 = fair, 3 = good, 4 = very good) and recorded
only once before patient discharge from the hospital, all post-
operative variables were recorded on the 1st, 4th, 8th, 12th and
24th hours after end of surgery.
2.1. Statistical analysis
A power analysis was performed using a power of 80% and an
a value 0.05. We assumed that the difference between means of
the two groups for VAS would be 0.77 with an average stan-
dard deviation 1.19. The sample size was calculated to be 38
patients, so we decided to include 40 patients in each group
in the study. We used GraphPad Stat Mate version 2 statistics
program for power analysis.
Statistical analysis was done using SPSS program. Descrip-
tive statistics were expressed as mean + SD unless otherwise
stated. Student’s t-test was used for comparison of the means
of continuous variables and normally distributed data. The
Mann–Whitney U-test or Chi-square test was used otherwise.
P-value < 0.05 was considered statistically signiﬁcant.
3. Results
The two groups were comparable with respect to age, sex,
weight, height and duration of surgery (Table 1). For VAS
of pain at rest, there was a signiﬁcant decrease in pregabalin
group (group II) at 1 h, 4 h and 8 h postoperatively compared
to placebo group (group I) and insigniﬁcant difference between
the two groups at 12 h and 24 h after the end of surgery (Ta-
ble 2). Also, nalbuphine consumption (Table 3) showed a sig-
niﬁcant decrease in pregabalin group at 1 h, 4 h and 8 h
postoperatively compared to placebo group with a signiﬁcant
difference between the two groups in relation to total nalbu-
phine consumption during the whole 24 h (P< 0.003). The
study showed a signiﬁcant increase in NSS (Table 4) in pregab-
alin group at 1st and 4th postoperative hrs and insigniﬁcant in-
crease at 8th, 12th and 24th postoperative hrs compared to
placebo group. In relation to patient satisfaction to pain and
Table 2 Visual Analogue Scale (VAS) for postoperative pain
during 24 h.
Group I Group II P-value
1 h Postoperative 5.8 ± 1.32 4.65 ± 1.53* 0.015
4 h 4.5 ± 1.54 3.1 ± 1.02* 0.002
8 h 3.65 ± 1.27 2.6 ± 1.23* 0.011
12 h 2.75 ± 1.41 2.35 ± 0.99 0.306
24 h 1.95 ± 0.83 2.1 ± 0.79 0.562
Group I: placebo and Group II: pregabalin.
* P < 0.05 signiﬁcant between two groups. Data were expressed as
mean ± standard deviation.
Table 3 Nalbuphine consumption during 24 h.
Group I Group II P-value
1 h 14.4 ± 1.01 10 ± 1.03 <0.001
4 h 11.6 ± 0.62 8.4 ± 1.28 <0.001
8 h 10.4 ± 1.01 8 ± 1.85* 0.015
12 h 5.6 ± 2.14 3.8 ± 1.52 0.133
24 h 4.4 ± 0.94 3.6 ± 1.21 0.25
Total (24 h) 46.4 + 5.72 33.8 + 6.89* <0.003
Group I: placebo and Group II: pregabalin.
 P < 0.001 high signiﬁcant.
* P < 0.05 between two groups. Data were expressed as
mean ± standard deviation.
Table 4 Numeric sedation score during 24 h.
Group I Group II P-value
1 h 2.2 ± 0.82 2.75 ± 0.82* 0.042
4 h 2.1 ± 0.47 2.6 ± 0.99* 0.048
8 h 1.93 ± 0.92 2.45 ± 1.23 0.138
12 h 1.6 ± 0.82 2.0 ± 0.89 0.148
24 h 1.35 ± 0.49 1.65 ± 0.89 0.195
Group I: placebo and Group II: pregabalin.  P< 0.05 signiﬁcant
between two groups. Data were expressed as mean ± standard
deviation.
Table 6 Adverse effects in both groups.
Group I Group II
Nausea 12 (30%) 10 (25%)
Vomiting 10 (25%) 6 (15%)
Dizziness 8 (20%) 10 (25%)
Somnolence 8 (20%) 12 (30%)
Headache 2 (5%) 4 (10%)
Blurred vision 0 (0%) 4 (10%)
Urine retention 14 (35%) 8 (20%)
Pruritus 16 (40%) 6 (15%)
Shivering 16 (40%) 2 (5%)*
Group I: placebo and Group II: pregabalin.
* P< 0.05 signiﬁcant between two groups. Data were presented as
number of patients and (percentage).
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(Table 5), there was an overall high signiﬁcant increase
(P< 0.001) in the pregabalin group compared to placebo
group, as in group II (pregabalin group), 15 patients showed
very good satisfaction (37.5%), 20 good (50%), 4 fair (10%)
and 1 poor satisfaction (2.5%) in comparison with only 6 pa-
tients (15%) in placebo group showed good satisfaction, 20Table 5 Patient satisfaction.
Group I Group II
Poor 14 (35%) 1 (2.5%)
Fair 20 (50%) 4 (10%)
Good 6 (15%) 20 (50%)
Very good 0 (0%) 15 (37.5%)
Group I: placebo and Group II: pregabalin.
 P< 0.001 signiﬁcant between two groups. Data were presented
as number of patients and (percentage).fair (50%) and 14 poor satisfaction (35%). Table 6 showed
the adverse effects reported during the study, as there were
an increase in patients number suffering from dizziness, som-
nolence, headache and blurred vision and a decrease in patient
number suffering from nausea, vomiting, urine retention and
pruritus in pregabalin group compared to placebo group with
insigniﬁcant difference between the two groups in all the above
side effects. Postoperative shivering is signiﬁcantly lower in
pregabalin group than in placebo group (P< 0.05).
4. Discussion
The present study showed a signiﬁcant decrease in pain score
and nalbuphine consumption with an increase in sedation
score during the 1st, 4th and 8th hrs postoperative in pregab-
alin group compared to placebo. During the later hours of
study, there was no difference in the previous measures be-
tween the studied groups. These ﬁndings are in accordance
with the pharmacokinetic proﬁle of the drug as it has short
elimination life (6–8 h) after a single dose [19,20].
The probable mechanism of action of pregabalin via, po-
tent binding at a2-d subunit of the presynaptic, voltage-gated
calcium channels that are widely distributed throughout the
peripheral and central nervous system [8–10], this reduces cal-
cium inﬂux at nerve terminals and therefore reduces the release
of several neurotransmitters including glutamate, norepineph-
rine and substance P [11,12]. Also, the sensitization of dorsal
horn neurons has been demonstrated in acute pain models
[21,22] and possibly plays a role in the development of chronic
pain after surgery [23,24]. By reducing the hyperexcitability of
dorsal horn neurons induced by tissue damage, pregabalin may
have a role in postoperative pain management [25–27].
Pregabalin has been used in doses starting from 50 [28], 75
[29], 100 [13], 150 [15], 300 mg [30,31] and 600 mg [14]. The
300 mg dose of pregabalin used in our study was considered
the basis in many studies [30,31]. This dose has been well toler-
ated except forminor side effects like dizziness and sedation [32].
Also, pregabalin in the present study had a high percentage
and signiﬁcant increase in patient satisfaction and signiﬁcant
decrease in total nalbuphine consumption in relation to pla-
cebo. These ﬁndings were combatable with the study was done
by Ittichaikulthol and colleagues [30] who found 300 mg 1 h be-
fore surgery, signiﬁcantly reduced pain scores and morphine
consumption after abdominal hysterectomy. Hill and co-work-
ers [16] found that 300 mg pregabalin to be more effective than
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dental extraction. Also, Kim and others [33] showed pregabalin
150 mg 1 h before surgery and repeated after 12 h was effective
in reducing postoperative pain in patients undergoing robot-as-
sisted endoscopic thyroidectomy. Peng and others [28] reported
low-dose pregabalin (75 mg) had given 1 h before surgery and
then every 12 h for three doses, signiﬁcantly reduced pain
scores in patients after doing laparoscopic cholecystectomy.
On the other hand, other studies were done by Paech and
colleagues [13], Jokela and others [14] andWhite and colleagues
[34] reported that preoperative administration of pregabalin
100, 300 or 75–300 mg, respectively, was ineffective in reducing
postoperative pain and the need for opioid analgesic medica-
tion. This can be explained ﬁrstly by using low doses of pregab-
alin 75, 100 and 150 which are ineffective to produce
satisfactory level of analgesia, secondly the type of surgical pro-
cedures which were minor and superﬁcial surgeries and so they
have been use small doses of pregabalin in the previous studies
and thirdly only a single dose of the medication was adminis-
tered before surgery, while in our study we used 300 mg pregab-
alin, twice doses 12 h apart preoperative for patients scheduled
to a painful operation (shoulder arthroscopy). Pregabalin is
generally well tolerated [35] and associated with transient mild
to moderate adverse effects which are dose dependent.
Dizziness and somnolence are most frequently reported side
effects of pregabalin (22–29%) [36]. The present study ap-
proved this as: dizziness and somnolence were the most com-
mon side effects, 25–30% respectively in pregabalin group
with insigniﬁcant difference between it and placebo. The same
results reported by Gajraj [19] who found that somnolence
(29.2%) and dizziness (22.2%) and Ittichaikulthol and col-
leagues [30] who found the same results, dizziness and somno-
lence (34.21%).
Postoperative shivering is physiologically stressful and
unpleasant effect and occurs in 6.3–66% of patients recovering
from general anaesthesia [37]. The present study showed signif-
icant decrease in postoperative shivering in pregabalin group
which may be due to anticonvulsive, anxiolytic and analgesic
effects of gabapentinoids may partly reduce the incidence of
shivering, but the exact mechanism of pregabalin in postoper-
ative shivering is still unexplained. So many future studies will
be needed to focus on the effects of gabapentoids on shivering.
In conclusion, the present study demonstrated that twice,
preoperative doses of pregabalin 300 mg (12 h apart) in pa-
tients undergoing shoulder arthroscopy resulted in signiﬁcant
reduction in pain score, nalbuphine requirement and a signiﬁ-
cant increase in patient satisfaction in 24 h postoperatively
without signiﬁcant side effects. So, the study recommends
twice, 12 h apart, 300 mg of pregabalin oral preoperatively is
a safe, effective and opioid-sparing method for multimodal
analgesia in postoperative pain after shoulder arthroscopy.
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